PMID- 32569234
OWN - NLM
STAT- MEDLINE
DCOM- 20200720
LR  - 20221005
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 25
DP  - 2020 Jun 19
TI  - Therapeutic potential of targeting MYCN: A case series report of neuroblastoma 
      with MYCN amplification.
PG  - e20853
LID - 10.1097/MD.0000000000020853 [doi]
LID - e20853
AB  - INTRODUCTION: Neuroblastoma (NB) with MYCN amplification has a poor prognosis and 
      high mortality. The potential molecular biological relationship between clinical 
      features and MYCN amplification should be explored. METHODS: NB patients were 
      examined by fluorescence in situ hybridization (FISH) for MYCN amplification in 
      the tumor mass or bone marrow samples to determine whether MYCN was amplified. A 
      series of eleven MYCN-amplified NB patients were included. The age, primary site, 
      tumor size, specific biomarkers, and invaded organs were analyzed. All patients 
      accepted standardized treatment of surgery, chemotherapy, and radiotherapy. 
      Progression-free survival (PFS) and overall survival (OS) were evaluated. 
      RESULTS: The median age at diagnosis was 24 months. Nine patients (81.8%) were in 
      stage IV, with high serum neuron-specific enolase (NSE) expression, normal urine 
      vanillylmandelic acid (VMA) level and extensive metastases. All patients accepted 
      a chemotherapy protocol with 8 to 10 cycles, and 9 patients (81.8%) were 
      sensitive to the initial chemotherapy protocol. At the end of follow-up, four 
      patients (36.3%) died with a median OS of 15 months. Five patients (45%) survived 
      with a median PFS of 13 months. Two patients were still receiving chemotherapy. 
      CONCLUSION: Given the effect of MYCN amplification on poor outcome in NB, novel 
      treatments targeting MYCN should be developed for patients with NB.
FAU - Huang, Can
AU  - Huang C
AD  - Department of Hematology and Oncology, Children's Hospital of Shanghai, Shanghai 
      Jiao Tong University, Shanghai, China.
FAU - Jiang, Shayi
AU  - Jiang S
FAU - Yang, Jingwei
AU  - Yang J
FAU - Liao, Xuelian
AU  - Liao X
FAU - Li, Yanhua
AU  - Li Y
FAU - Li, Shanshan
AU  - Li S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (MYCN protein, human)
RN  - 0 (N-Myc Proto-Oncogene Protein)
SB  - IM
MH  - Child, Preschool
MH  - Combined Modality Therapy
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Infant
MH  - Male
MH  - N-Myc Proto-Oncogene Protein/*metabolism
MH  - Neuroblastoma/metabolism/mortality/*pathology/therapy
MH  - Survival Analysis
PMC - PMC7310875
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2020/06/23 06:00
MHDA- 2020/07/21 06:00
PMCR- 2020/06/19
CRDT- 2020/06/23 06:00
PHST- 2020/06/23 06:00 [entrez]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2020/07/21 06:00 [medline]
PHST- 2020/06/19 00:00 [pmc-release]
AID - 00005792-202006190-00082 [pii]
AID - MD-D-19-10197 [pii]
AID - 10.1097/MD.0000000000020853 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Jun 19;99(25):e20853. doi: 
      10.1097/MD.0000000000020853.